108 related articles for article (PubMed ID: 19418956)
1. Efficacy of pegylated lyposomal anthracyclines and of intra-arterial carboplatin and doxorubicin combined with local hyperthermia in a case of malignant endovascular papillary angioendothelioma.
Fiorillo A; DeRosa G; Giugliano F; DeLillo ML; Sabbatino MS; Veneziano A
Curr Drug Deliv; 2009 Jan; 6(1):58-61. PubMed ID: 19418956
[TBL] [Abstract][Full Text] [Related]
2. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.
Pignata S; Lauraine EP; du Bois A; Pisano C
Crit Rev Oncol Hematol; 2010 Jan; 73(1):23-30. PubMed ID: 19782576
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].
Zvaríková M
Klin Onkol; 2011; 24(6):475-6. PubMed ID: 22268244
[No Abstract] [Full Text] [Related]
6. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sequential chemotherapy including methotrexate and doxorubicin in an infant with partially resected choroid plexus carcinoma.
Fiorillo A; Maggi G; Cirillo S; Migliorati R; Buffardi F; Alfieri E; Sabbatino MS; D'Amico A; DelBasso DeCaro ML
Pediatr Neurosurg; 2003 Jan; 38(1):21-6. PubMed ID: 12476023
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.
Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C
Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382
[TBL] [Abstract][Full Text] [Related]
10. [Pegylated liposomal doxorubicin in ovarian cancer treatment].
Nowak-Markwitz E
Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461
[TBL] [Abstract][Full Text] [Related]
11. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
12. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
Rakowski JA; Ahmad S; Holloway RW
Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).
Harter P; Sehouli J; Reuss A; Baumann K; Hanker L; Kimmig R; Schröder W; Burges A; Gropp-Meier M; Kurzeder C; Mahner S; Canzler U; Lück HJ; Meier W; Fehm T; du Bois A
Int J Gynecol Cancer; 2016 Nov; 26(9):1636-1641. PubMed ID: 27654266
[TBL] [Abstract][Full Text] [Related]
14. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
Romeo C; Joly F; Ray-Coquard I; El Kouri C; Mercier-Blas A; Berton-Rigaud D; Kalbacher E; Cojocarasu O; Fabbro M; Cretin J; Zannetti A; Abadie-Lacourtoisie S; Mollon D; Hardy-Bessard AC; Provansal M; Blot E; Delbaldo C; Lesoin A; Freyer G; You B
Gynecol Oncol; 2019 Jan; 152(1):68-75. PubMed ID: 30446275
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
